Toggle Health Problems and D

More COVID vaccinations, more infections - Cleveland Clinic - Dec 2022

Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine

medRxiv preprint Dec 19, 2022 doi: https://doi.org/10.1101/2022.12.17.22283625
Nabin K. Shrestha,1l shrestn@ccf.org; Patrick C. Burke,2 Amy S. Nowacki,3 James F. Simon,4 Amanda Hagen,5 Steven M. Gordon
1 departments of Infectious Diseases, 2Infection Prevention, Quantitative Health Sciences, 4Enterprise Business Intelligence, and Occupational Health, Cleveland Clinic, Cleveland, Ohio, USA.



Summary: Among 51011 working-aged Cleveland Clinic employees, the bivalent COVID-19 vaccine booster was 30% effective in preventing infection, during the time when the virus strains dominant in the community were represented in the vaccine.

Background. The purpose of this study was to evaluate whether a bivalent COVID-19 vaccine protects against COVID-19.

Methods. Employees of Cleveland Clinic in employment on the day the bivalent COVID-19 vaccine first became available to employees, were included. The cumulative incidence of COVID-19 was examined over the following weeks. Protection provided by vaccination (analyzed as a time-dependent covariate) was evaluated using Cox proportional hazards regression. The analysis was adjusted for the pandemic phase when the last prior COVID-19 episode occurred, and the number of prior vaccine doses received.

Results. Among 51011 employees, 20689 (41%) had had a previous documented episode of COVID-19, and 42064 (83%) had received at least two doses of a COVID-19 vaccine. COVID-19 occurred in 2452 (5%) during the study. Risk of COVID-19 increased with time since the most recent prior COVID-19 episode and with the number of vaccine doses previously received. In multivariable analysis, the bivalent vaccinated state was independently associated with lower risk of COVID-19 (HR, .70; 95% C.I., .61 -.80), leading to an estimated vaccine effectiveness (VE) of 30% (95% CI, 20-39%).
Compared to last exposure to SARS-CoV-2 within 90 days, last exposure 6-9 months previously was associated with twice the risk of COVID-19, and last exposure 9-12 months previously with 3.5 times the risk.

Conclusions. The bivalent COVID-19 vaccine given to working-aged adults afforded modest protection overall against COVID-19, while the virus strains dominant in the community were those represented in the vaccine.
 Download the PDF from VitaminDWiki

This preprint was discussed in Dr. Campbell video - Jan 4, 2023

Video was removed by YouTube the next day
: Dr. Campbell asked why this sort of study was not done years ago by the CDC, FDA, etc.

Studies with similar conclusions in VitaminDWiki

Attached files

ID Name Comment Uploaded Size Downloads
19063 Infection risk table.jpg admin 05 Jan, 2023 14.73 Kb 8188
19062 infection vs vaccination.jpg admin 05 Jan, 2023 84.01 Kb 4759
19061 More vax, more infections pp on Campbell_CompressPdf.pdf admin 05 Jan, 2023 187.53 Kb 480